These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Efficacy and safety of glucagon-like peptide-1 receptor agonists in type 2 diabetes: A systematic review and mixed-treatment comparison analysis. Htike ZZ; Zaccardi F; Papamargaritis D; Webb DR; Khunti K; Davies MJ Diabetes Obes Metab; 2017 Apr; 19(4):524-536. PubMed ID: 27981757 [TBL] [Abstract][Full Text] [Related]
3. GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art. Nauck MA; Quast DR; Wefers J; Meier JJ Mol Metab; 2021 Apr; 46():101102. PubMed ID: 33068776 [TBL] [Abstract][Full Text] [Related]
4. An overview of once-weekly glucagon-like peptide-1 receptor agonists--available efficacy and safety data and perspectives for the future. Madsbad S; Kielgast U; Asmar M; Deacon CF; Torekov SS; Holst JJ Diabetes Obes Metab; 2011 May; 13(5):394-407. PubMed ID: 21208359 [TBL] [Abstract][Full Text] [Related]
5. Long-acting GLP-1RAs: An overview of efficacy, safety, and their role in type 2 diabetes management. Chun JH; Butts A JAAPA; 2020 Aug; 33(8):3-18. PubMed ID: 32740121 [TBL] [Abstract][Full Text] [Related]
6. Glucagon-like peptide-1 receptor agonists in type 2 diabetes treatment: are they all the same? Gentilella R; Pechtner V; Corcos A; Consoli A Diabetes Metab Res Rev; 2019 Jan; 35(1):e3070. PubMed ID: 30156747 [TBL] [Abstract][Full Text] [Related]
7. Long-acting GLP-1RAs: An overview of efficacy, safety, and their role in type 2 diabetes management. Chun JH; Butts A JAAPA; 2020 Aug; 33(S8 Suppl 1):3-18. PubMed ID: 32756220 [TBL] [Abstract][Full Text] [Related]
8. Glycaemic and non-glycaemic efficacy of once-weekly GLP-1 receptor agonists in people with type 2 diabetes. Patel D J Clin Pharm Ther; 2020 Sep; 45 Suppl 1(Suppl 1):28-42. PubMed ID: 32910489 [TBL] [Abstract][Full Text] [Related]
9. Cardiovascular safety outcomes of once-weekly GLP-1 receptor agonists in people with type 2 diabetes. Goldman JD J Clin Pharm Ther; 2020 Sep; 45 Suppl 1(Suppl 1):61-72. PubMed ID: 32910492 [TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of once-weekly glucagon-like peptide-1 receptor agonists compared with exenatide and liraglutide in type 2 diabetes: a systemic review of randomised controlled trials. Xue X; Ren Z; Zhang A; Yang Q; Zhang W; Liu F Int J Clin Pract; 2016 Aug; 70(8):649-56. PubMed ID: 27456750 [TBL] [Abstract][Full Text] [Related]
11. The Role of the Pharmacist in Managing Type 2 Diabetes with Glucagon-Like Peptide-1 Receptor Agonists as Add-On Therapy. Meece J Adv Ther; 2017 Mar; 34(3):638-657. PubMed ID: 28210986 [TBL] [Abstract][Full Text] [Related]
12. Differential effects of glucagon-like peptide-1 receptor agonists on heart rate. Lorenz M; Lawson F; Owens D; Raccah D; Roy-Duval C; Lehmann A; Perfetti R; Blonde L Cardiovasc Diabetol; 2017 Jan; 16(1):6. PubMed ID: 28086882 [TBL] [Abstract][Full Text] [Related]
13. Treatment patterns in patients with type 2 diabetes mellitus treated with glucagon-like peptide-1 receptor agonists: Higher adherence and persistence with dulaglutide compared with once-weekly exenatide and liraglutide. Alatorre C; Fernández Landó L; Yu M; Brown K; Montejano L; Juneau P; Mody R; Swindle R Diabetes Obes Metab; 2017 Jul; 19(7):953-961. PubMed ID: 28181725 [TBL] [Abstract][Full Text] [Related]
18. Oral semaglutide versus injectable glucagon-like peptide-1 receptor agonists: a cost of control analysis. Hansen BB; Nuhoho S; Ali SN; Dang-Tan T; Valentine WJ; Malkin SJP; Hunt B J Med Econ; 2020 Jun; 23(6):650-658. PubMed ID: 31990244 [No Abstract] [Full Text] [Related]
19. A Plethora of GLP-1 Agonists: Decisions About What to Use and When. Samson SL; Garber AJ Curr Diab Rep; 2016 Dec; 16(12):120. PubMed ID: 27766579 [TBL] [Abstract][Full Text] [Related]
20. Managing the multifaceted nature of type 2 diabetes using once-weekly injectable GLP-1 receptor agonist therapy. Bzowyckyj A J Clin Pharm Ther; 2020 Sep; 45 Suppl 1(Suppl 1):7-16. PubMed ID: 32910488 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]